The US Food and Drug Administration is allowing sponsors to use the 510(k) pathway for photoplethysmograph analysis software two years after the agency authorized using, in an app Apple markets as part of its health suite on its Apple Watch, the analysis which detects blood volume changes in the skin to measure a user’s heart rate and blood volume.
In a final order published the the 4 February Federal Register, the FDA said it codified its decision to classify OTC photoplethysmograph analysis software as class II devices with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?